Diminished Expression of MiR-15a Is an Independent Prognostic Marker for Breast Cancer Cases

被引：0

作者：

Shinden, Yoshiaki ^{[1
]}

Akiyoshi, Sayuri ^{[2
]}

Ueo, Hiroki ^{[1
]}

Nambara, Syo ^{[1
]}

Saito, Tomoko ^{[1
]}

Komatsu, Hisateru ^{[1
]}

Ueda, Masami ^{[1
]}

Hirata, Hidenari ^{[1
]}

Sakimura, Shotaro ^{[1
]}

Uchi, Ryutaro ^{[1
]}

Takano, Yuki ^{[1
]}

Iguchi, Tomohiro ^{[1
]}

Eguchi, Hidetoshi ^{[1
]}

Sugimachi, Keishi ^{[1
]}

Kijima, Yuko ^{[3
]}

Ueo, Hiroaki ^{[4
]}

Natsugoe, Shoji ^{[3
]}

Mimori, Koshi ^{[1
]}

机构：

[1] Kyushu Univ, Beppu Hosp, Dept Surg, Beppu, Oita 8740838, Japan

[2] Kyushu Canc Ctr, Natl Hosp Org, Minami Ku, Fukuoka, Japan

[3] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Digest Surg Breast & Thyroid Surg, Sakuragaoka, Kagoshima, Japan

[4] Ueo Breast Surg Hosp, Haya, Oita, Japan

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 01期

基金：

日本学术振兴会;

关键词：

miR-15a; breast cancer; prognosis; MICRORNAS;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: MiR-15a targets Cyclin El (CCNE1), which regulates the cell cycle and promotes cell proliferation and progression. Herein, we investigated the clinicopathological significance of miR-15a as a prognostic marker in breast cancer (BC) cases. Materials and Methods: We collected primary tumor samples of 230 BC cases, including 68 triple-negative cases. The expression levels of miR-15a in primal), tumors were measured by qRT-PCR assay. Results: Low expression of miR-15a in primary tumors was significantly correlated with shorter disease-free survival (p=0.0012) and overall survival (p=0.005) compared to the high miR-15a expression in triple-negative BC cases. Multivariate analysis indicated that low rniR-15a expression was an independent prognostic factor for overall survival [RR=2.56(1.03-7.18), p=0.04]. Conclusion: MiR-15a expression levels could be a promising biological and prognostic marker for overall survival especially in triple-negative BC cases.

引用

页码：123 / 127

页数：5

共 50 条

[1] Quantitative assessment of miR34a as an independent prognostic marker in breast cancer
Agarwal, Seema
Hanna, J.
Sherman, M. E.
Figueroa, J.
Rimm, D. L.
BRITISH JOURNAL OF CANCER, 2015, 112 (01) : 61 - 68
[2] Quantitative assessment of miR34a as an independent prognostic marker in breast cancer
Seema Agarwal
J Hanna
M E Sherman
J Figueroa
D L Rimm
British Journal of Cancer, 2015, 112 : 61 - 68
[3] RECK is not an independent prognostic marker for breast cancer
Gomes, Luciana R.
Fujita, Andre
Mott, Joni D.
Soares, Fernando A.
Labriola, Leticia
Sogayar, Mari C.
BMC CANCER, 2015, 15
[4] RECK is not an independent prognostic marker for breast cancer
Luciana R. Gomes
André Fujita
Joni D. Mott
Fernando A. Soares
Leticia Labriola
Mari C. Sogayar
BMC Cancer, 15
[5] Diagnostic and Prognostic Value of Serum miR-15a and miR-16-1 Expression Among Egyptian Patients with Prostate Cancer
Zidan, Haidy E.
Abdul-Maksoud, Rehab S.
Elsayed, Walid S. H.
Desoky, Esam A. M.
IUBMB LIFE, 2018, 70 (05) : 437 - 444
[6] Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer
Hachim, Ibrahim Y.
Hachim, Mahmood Y.
Lopez, Vanessa M.
Lebrun, Jean-Jacques
Ali, Suhad
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (04) : 238 - 245
[7] EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases
Zehni, Alaleh Zati
Jeschke, Udo
Hester, Anna
Kolben, Thomas
Ditsch, Nina
Jacob, Sven-Niclas
Mumm, Jan-Niclas
Heidegger, Helene Hildegard
Mahner, Sven
Vilsmaier, Theresa
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 11
[8] miR-30e* is an independent subtype-specific prognostic marker in breast cancer
F D'Aiuto
M Callari
M Dugo
G Merlino
V Musella
P Miodini
B Paolini
V Cappelletti
M G Daidone
British Journal of Cancer, 2015, 113 : 290 - 298
[9] miR-30e* is an independent subtype-specific prognostic marker in breast cancer
Shah, M. Y.
Calin, G. A.
BREAST DISEASES, 2016, 27 (01): : 44 - 45
[10] miR-30e*is an independent subtype-specific prognostic marker in breast cancer
D'Aiuto, F.
Callari, M.
Dugo, M.
Merlino, G.
Musella, V.
Miodini, P.
Paolini, B.
Cappelletti, V.
Daidone, M. G.
BRITISH JOURNAL OF CANCER, 2015, 113 (02) : 290 - 298

← 1 2 3 4 5 →